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The potentially harmful effects of antidepressants, one of
the most prescribed groups of drugs worldwide, have been
the subject of some debate. In 2004, the US Food and Drug
Administration issued a ‘black-box’ warning on antide-
pressants (so called because the advisory text on the pack-
age insert is required to be framed by a black border), after
its own systematic review indicated that such therapy was
associated with an elevated risk of suicidal thinking, feeling
and behaviour in young people.1,2 In this issue of the
International Journal of Epidemiology, Azevedo Da Silva
and co-workers make a timely and important contribution
to the evidence base for another controversial potential
side effect: antidepressant medication might predispose
individuals to type 2 diabetes.3
The safety of drugs is carefully tested in randomized
controlled studies before approval, but most trials offer
only a relatively short period of surveillance. When the
side effects are rare and/or have an extended induction
period, they may be missed in these otherwise well-
conducted studies. Numerous chronic diseases, including
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diabetes, have been shown to develop over several years
and may plausibly represent an unforeseen effect of antide-
pressant medication, not least because early studies sug-
gested some antidepressants have a role in weight gain.
Data on disease diagnoses are routinely collected in
many high-income countries, and these records allow an
examination of the slowly developing effects of medication
use that could not be captured in the initial trials. One
such early study was a nested case-control analysis within
the General Practice Research Database which contains
electronic medical records of more than 6.4 million UK-
based individuals registered with a primary care physician
between 1990 and 2005. In the 15-year follow-up, people
who had used antidepressants for 2 years or more experi-
enced almost a doubling of later diabetes risk compared
with non-users.4 Several other studies utilizing medical
records or questionnaire data on physician-diagnosed dia-
betes reported similarly worrisome findings.5–9 As diabetes
causes well-documented damage tovarious organs, includ-
ing eyes, kidneys, heart and brain, and reduces life expect-
ancy, findings suggesting a link between a commonly used
medication and this disease predictably attracted world-
wide media attention.
A major limitation in studies supporting the antidepres-
sant use-diabetes association, however, was their reliance
on diagnosed diabetes. If antidepressant use truly increases
the risk of diabetes, an association would also be expected
with undiagnosed disease as well as the metabolic changes
that precede diabetes onset, such as elevated fasting glu-
cose and impaired glucose tolerance. In the UK Whitehall
II study, glucose levels have been assessed repeatedly over
time in clinical examinations facilitating identification of
undiagnosed diabetes to supplement extant data on diag-
nosed diabetes.10 In accordance with results from other
studies,5–9 antidepressant users experienced about three
times the risk of physician-diagnosed diabetes observed in
non-users.11 Antidepressant use was not, however, associ-
ated with undiagnosed diabetes at any follow-up examina-
tion, nor was it associated with repeat measures of fasting
or post-load glucose levels.10 The US National Health and
Nutrition Examination Study (NHANES), another highly
phenotyped study, closely replicated this pattern of results:
a link between antidepressant use and diagnosed diabetes
but no association with undiagnosed diabetes.11
Using data from DESIR, an unusually well-character-
ized population-based cohort study primarily established
to examine the insulin resistance syndrome, Azevedo Da
Silva and co-workers bring more evidence to bear on the
antidepressant medication-diabetes controversy.3 The
investigators examined changes over time in b-cell function
(HOMA2-%B) and insulin sensitivity (HOMA2-%S), in
addition to glucose levels, using repeat data over a 9-year
follow-up in 4700 French adults.3 Capturing this wide
array of biomarkers is useful because impaired b-cell func-
tion and reduced insulin sensitivity are among the key
pathological changes leading to hyperglycaemia and type
2 diabetes. Again, antidepressant use was not associated
with change in any of the biomarkers of diabetes metabo-
lism. The findings from the DESIR study,3 in combination
with others,10,11 therefore raise serious doubts about the
potential causal role of antidepressant medication in the
development of diabetes.
What could explain the apparent discrepancy between,
on the one hand, medical record-based studies and, on the
other, highly phenotyped, ‘bespoke’ cohort studies? As
Azevedo Da Silva and others suggest, disease ascertain-
ment bias is a possibility.3 Antidepressant use may increase
the likelihood of being diagnosed with diabetes because
people undergoing treatment for depression, owing to their
more frequent contact with healthcare providers, are also
more likely to be diagnosed with other ailments. This
would have the effect of generating a spurious association
between antidepressant use and diabetes when using elec-
tronic medical records only or relying on self-reports of
diagnosed diseases only, but would not bias the association
with undiagnosed diabetes or diabetes biomarkers.
Current research strategies emphasize ‘big data’
approaches, including linkage to electronic medical
records, as a cost-effective means of minimizing random
error and therefore producing precise (although not
necessarily bias free) measures of effect. The new findings
by Azevedo Da Silva and colleagues, allied to a series of
similar investigations, illustrate that highly phenotyped
cohort studies with long follow-up continue to have a cru-
cial role if we are to obtain reliable evidence on disease
aetiology.
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